PADELIPORFIN POTASSIUM

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C37H41N5O9S.2K.Pd
Molecular Weight	916.43
Optical Activity	UNSPECIFIED
Defined Stereocenters	4 / 4
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[K+].[K+].[Pd++].CC[C@@H]1[C@@H](C)C2=NC1=CC3=C(C)C(C(=O)NCCS([O-])(=O)=O)=C([N-]3)C(CC(=O)OC)=C4N=C(C=C5[N-]C(=C2)C(C(C)=O)=C5C)[C@@H](C)[C@@H]4CCC([O-])=O

InChI

InChIKey=AOSMIFSJINLACN-NAEAMVODSA-J

InChI=1S/C37H45N5O9S.2K.Pd/c1-8-22-17(2)25-16-30-33(21(6)43)19(4)27(40-30)14-26-18(3)23(9-10-31(44)45)35(41-26)24(13-32(46)51-7)36-34(37(47)38-11-12-52(48,49)50)20(5)28(42-36)15-29(22)39-25;;;/h14-18,22-23H,8-13H2,1-7H3,(H5,38,39,40,41,42,43,44,45,47,48,49,50);;;/q;2*+1;+2/p-4/t17-,18+,22-,23+;;;/m1.../s1

HIDE SMILES / InChI

Molecular Formula	K
Molecular Weight	39.0983
Charge	1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	Pd
Molecular Weight	106.42
Charge	2
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C37H43N5O9S
Molecular Weight	733.83
Charge	-2
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	4 / 4
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/padeliporfin | https://www.ema.europa.eu/en/documents/product-information/tookad-epar-product-information_en.pdf | https://www.ncbi.nlm.nih.gov/pubmed/28007457

Padeliporfin is a vascular-acting photosensitizer consisting of a water-soluble, palladium-substituted bacteriochlorophyll derivative with antineoplastic activity. After administration, the drug is activated locally when the tumor bed is exposed to low-power laser light; reactive oxygen species (ROS) are formed upon activation and ROS-mediated necrosis may occur at the site of interaction between the photosensitizer, light and oxygen. Padeliporfin is approved in Europe for the treatment of adult patients with previously untreated, unilateral, low-risk, adenocarcinoma of the prostate and is marketed under tradename TOOKAD.

Approval Year

Substance Class	Chemical Created by `admin` on `Wed Apr 02 01:00:31 GMT 2025` Edited by `admin` on `Wed Apr 02 01:00:31 GMT 2025`
Record UNII	JQ72VD4XUL
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

STAKEL

Preferred Name

English

PADELIPORFIN POTASSIUM

Official Name

English

Padeliporfin dipotassium [WHO-DD]

Common Name

English

PADELIPORFIN (POTASSIUM)

Common Name

English

Potassium (SP-4-2)-[(7S,8S,17R,18R)-13-acetyl-18-ethyl-7,8-dihydro-5-(2-methoxy-2-oxoethyl)-2,8,12,17-tetramethyl-3-[(2-sulfoethyl)carbamoyl]-21H,23H-porphine-7-propanoato(4-)-?N21,?N22,?N23,?N24]-palladate(2-) (2:1)

Systematic Name

English

WST11 DIPOTASSIUM

Code

English

PALLADATE(2-), ((7S,8S,17R,18R)-13-ACETYL-18-ETHYL-7,8-DIHYDRO-5-(2-METHOXY-2-OXOETHYL)-2,8,12,17-TETRAMETHYL-3-(((2-SULFOETHYL)AMINO)CARBONYL)-21H,23H-PORPHINE-7-PROPANOATO(4-)-.KAPPA.N21,.KAPPA.N22,.KAPPA.N23,.KAPPA.N24)-, POTASSIUM (1:2), (SP-4-2)-

Systematic Name

English

PADELIPORFIN DIPOTASSIUM

Common Name

English

WST-11 DIPOTASSIUM

Code

English

PADELIPORFIN POTASSIUM [USAN]

Common Name

English

PADELIPORFIN DI-POTASSIUM [MI]

Common Name

English

Code System Code Type Description

USAN

HI-09